New strategies of mammary cancer vaccination

Breast Journal

Volumn 16, Issue SUPPL. 1, 2010, Pages

  Accolla, Roberto S ^a   Frangione, Valeria ^a   De Lerma Barbaro, Andrea ^a   Mortara, Lorenzo ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

CD4?+?T cells; CIITA; MHC II; tumor immunotherapy; tumor vaccine

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; GENE LOCUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL MEMORY; IN VIVO STUDY; MOUSE; NONHUMAN; SOLID TUMOR; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; GENES, MHC CLASS II; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; TRANSFECTION;

EID: 78649291630     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2010.01003.x     Document Type: Article

References (15)

1. Dudley ME, Rosenberg SA,. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666 -75.
2. Rosenberg SA, Yang JC, Restifo NP,. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909 -15.
3. Kennedy R, Celis E,. Multiple roles for CD4?+? T cells in anti-tumor immune responses. Immunol Rev 2008; 222: 129 -44.
4. Accolla RS, Scupoli MT, Cambiaggi C, Tosi G, S. S,. Cell lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression. Int J Cancer 1991; 6: 20 -5.
5. Steimle V, Otten LA, Zufferey M, Mach B,. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or Bare Lymphocyte Syndrome). Cell 1993; 75: 135 -46.
6. Accolla RS, Jotterand-Bellomo M, Scarpellino L, Maffei A, Carra G, Guardiola J,. Air-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. J Exp Med 1986; 164: 369 -74.
7. Sartoris S, Valle MT, De Lerma Barbaro A, Tosi G, Cestari T, D'Agostino A, M. MA, Manca F, Accolla RS,. HLA class II expression in uninducible hepatocarcinoma cells after trasfection of the AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity. J Immunol 1998; 161: 814 -20.
8. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S,. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997; 94: 6886 -91.
9. Brocker EB, Suter L, Sorg C,. HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol 1984; 82: 244 -7.
10. Sheen-Chen SM, Chou FF, Eng HL, Chen WJ,. An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer. Surgery 1994; 116: 510 -5.
11. Nanni P, De Giovanni C, Lollini PL, Nicoletti G, Prodi G,. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metast 1983; 1: 373 -80.
12. Meazza R, Comes A, Orengo AM, Ferrini S, Accolla RS,. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur J Immunol 2003; 33: 1183 -92.
13. Mortara L, Castellani P, Meazza R, Tosi G, De Lerma Barbaro A, Procopio FA, Comes A, Zardi L, Ferrini S, Accolla RS,. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin Cancer Res 2006; 12: 3435 -43.
14. Mortara L, Frangione V, Castellani P, De Lerma Barbaro A, Accolla RS,. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4?+? T cell priming and CD8?+? T cell effector functions. Int Immunol 2009; 21: 655 -65.
15. Frangione V, Mortara L, Castellani P, De Barbaro Lerma A, Accolla RS,. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of anti-tumor CD4?+? T lymphocytes for immunotherapy. Int J Cancer 2010; 127: 1614 -24.